SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: B.REVERE who wrote (4142)7/9/1998 9:26:00 PM
From: Anthony Wong  Respond to of 9523
 
BR, the Viagra sales would include those from the few foreign countries that have approved the drug (Brazil, the 2 or 3 small places in Europe) , though I don't expect those to be a significant no. The script no. should include those paid out of pocket by the patient. Earnings for the last quarter after EU approval should be interesting, judging by the hoopla presently in the UK.



To: B.REVERE who wrote (4142)7/9/1998 10:06:00 PM
From: Cosmo Daisey  Read Replies (1) | Respond to of 9523
 
BR,
"""Viagra added 411 mill in sales on 2.9 mill scripts. That averages out to around 14 pills per script, not the 8.5 that most analysts have been quoting. """

The additional pills are in the pipeline of wholesalers and on the shelf at pharms. PFE books the sales when they sell them, not when the customers buys them.
cdaiseyPhD@get-it-straight.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News